Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVL-330 in Advanced or Metastatic HER2-altered NSCLC
NCT06521554Phase 1Recruiting
- Sponsor
- Nuvalent
- Start
- Jul 2024
- Primary completion
- Jan 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 1, open-label trial of NVL-330 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Nuvalent. Primary endpoints: Recommended Phase 2 Dose at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
NVL-330
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06521554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06521554.